These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 26488196)

  • 21. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy.
    Goren A; Zou KH; Gupta S; Chen C
    Int J Clin Pract; 2014 Mar; 68(3):336-48. PubMed ID: 24372892
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics of antimuscarinic responders versus suboptimal responders in a randomized clinical trial of patients with overactive bladder symptoms.
    Grenabo L; Herschorn S; Kaplan SA; Cardozo L; Scholfield D; Arumi D; Carlsson M; Chapman D; Ntanios F
    Curr Med Res Opin; 2017 Oct; 33(10):1731-1736. PubMed ID: 28758802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
    Goldman HB; Oelke M; Kaplan SA; Kitta T; Russell D; Carlsson M; Arumi D; Mangan E; Ntanios F
    Int Urogynecol J; 2019 Feb; 30(2):239-244. PubMed ID: 29600400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients.
    Dell'Atti L
    Eur Rev Med Pharmacol Sci; 2015; 19(9):1559-63. PubMed ID: 26004592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Cardozo L; Thorpe A; Warner J; Sidhu M
    BJU Int; 2010 Aug; 106(4):506-14. PubMed ID: 20132203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.
    Arlandis-Guzman S; Errando-Smet C; Trocio J; Arumi D; Rejas J
    BMC Urol; 2011 May; 11():9. PubMed ID: 21599928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy - An Addendum.
    Geoffrion R
    J Obstet Gynaecol Can; 2017 Dec; 39(12):1221-1229. PubMed ID: 28986184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
    Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
    Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States.
    Ng DB; Espinosa R; Johnson SJ; Walker D; Gooch K
    J Med Econ; 2017 Dec; 20(12):1272-1280. PubMed ID: 28805473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
    Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
    BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
    Chapple C; Van Kerrebroeck P; Tubaro A; Haag-Molkenteller C; Forst HT; Massow U; Wang J; Brodsky M
    Eur Urol; 2007 Oct; 52(4):1204-12. PubMed ID: 17651893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fesoterodine: a new agent for treating overactive bladder.
    Ellsworth P; Berriman SJ; Brodsky M
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S115-7. PubMed ID: 19355800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.